Found 241 with Last Name = 'arnoult' and Initial = 'e' TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceutica
Curated by ChEMBL
Janssen Pharmaceutica
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Displacement of 3H-dofetilide from human ERGMore data for this Ligand-Target Pair
TargetCytochrome P450 1A2(Homo sapiens (Human))
Janssen Infectious Diseases Diagnostics
Curated by ChEMBL
Janssen Infectious Diseases Diagnostics
Curated by ChEMBL
Affinity DataIC50: 300nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceutica
Curated by ChEMBL
Janssen Pharmaceutica
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:Displacement of 3H-dofetilide from human ERGMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceutica
Curated by ChEMBL
Janssen Pharmaceutica
Curated by ChEMBL
Affinity DataIC50: 500nMAssay Description:Displacement of 3H-dofetilide from human ERGMore data for this Ligand-Target Pair
Affinity DataIC50: 650nMAssay Description:Inhibition of 5-HT2A receptor (unknown origin)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceutica
Curated by ChEMBL
Janssen Pharmaceutica
Curated by ChEMBL
Affinity DataIC50: 700nMAssay Description:Displacement of 3H-dofetilide from human ERGMore data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 740nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 830nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetCytochrome P450 1A2(Homo sapiens (Human))
Janssen Infectious Diseases Diagnostics
Curated by ChEMBL
Janssen Infectious Diseases Diagnostics
Curated by ChEMBL
Affinity DataIC50: 900nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceutica
Curated by ChEMBL
Janssen Pharmaceutica
Curated by ChEMBL
Affinity DataIC50: 900nMAssay Description:Displacement of 3H-dofetilide from human ERGMore data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 944nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 998nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.00E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.01E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.02E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.02E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.03E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.04E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.06E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.06E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.07E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.13E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.13E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.14E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.17E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.17E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.19E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.20E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceutica
Curated by ChEMBL
Janssen Pharmaceutica
Curated by ChEMBL
Affinity DataIC50: 1.20E+3nMAssay Description:Displacement of 3H-dofetilide from human ERGMore data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.23E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.26E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.29E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetCytochrome P450 1A2(Homo sapiens (Human))
Janssen Infectious Diseases Diagnostics
Curated by ChEMBL
Janssen Infectious Diseases Diagnostics
Curated by ChEMBL
Affinity DataIC50: 1.30E+3nMAssay Description:Inhibition of CYP1A2 (unknown origin)More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.35E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.41E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.43E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.44E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.45E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.46E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.47E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.50E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.51E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.54E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.54E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.54E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.55E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.59E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Janssen Pharmaceutica
Curated by ChEMBL
Janssen Pharmaceutica
Curated by ChEMBL
Affinity DataIC50: 1.60E+3nMAssay Description:Displacement of 3H-dofetilide from human ERGMore data for this Ligand-Target Pair
TargetEnoyl-[acyl-carrier-protein] reductase [NADPH] FabI(Staphylococcus aureus)
Janssen Ireland
US Patent
Janssen Ireland
US Patent
Affinity DataIC50: 1.61E+3nMAssay Description:FabI enzyme inhibition assays were carried out in half-area, 384-well microtitre plates. Compounds were evaluated in 40-μl assay mixtures contai...More data for this Ligand-Target Pair
